MA52366A - Anticorps anti-tl1a optimisés - Google Patents
Anticorps anti-tl1a optimisésInfo
- Publication number
- MA52366A MA52366A MA052366A MA52366A MA52366A MA 52366 A MA52366 A MA 52366A MA 052366 A MA052366 A MA 052366A MA 52366 A MA52366 A MA 52366A MA 52366 A MA52366 A MA 52366A
- Authority
- MA
- Morocco
- Prior art keywords
- optimized anti
- tl1a antibodies
- tl1a
- antibodies
- optimized
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862662605P | 2018-04-25 | 2018-04-25 | |
US201862756494P | 2018-11-06 | 2018-11-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA52366A true MA52366A (fr) | 2021-03-03 |
Family
ID=68295788
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA052366A MA52366A (fr) | 2018-04-25 | 2019-04-24 | Anticorps anti-tl1a optimisés |
Country Status (10)
Country | Link |
---|---|
US (4) | US20210070871A1 (fr) |
EP (1) | EP3784699A4 (fr) |
JP (2) | JP7332627B2 (fr) |
KR (1) | KR20210005169A (fr) |
CN (1) | CN112585165A (fr) |
AU (1) | AU2019261426A1 (fr) |
CA (1) | CA3098374A1 (fr) |
MA (1) | MA52366A (fr) |
TW (1) | TWI842707B (fr) |
WO (1) | WO2019209995A2 (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110121509B (zh) * | 2016-10-26 | 2024-05-07 | 西达-赛奈医疗中心 | 中和抗tl1a单克隆抗体 |
CN112585165A (zh) | 2018-04-25 | 2021-03-30 | 普罗米修斯生物科学公司 | 优化的抗tl1a抗体 |
CA3140029A1 (fr) | 2019-05-14 | 2020-11-19 | Prometheus Biosciences, Inc. | Methodes, systemes et dispositifs de selection de patient tl1a |
BR112022007720A2 (pt) | 2019-10-24 | 2022-08-23 | Prometheus Biosciences Inc | Anticorpos humanizados para ligante 1a tnf-like (tl1a) e seus usos |
WO2021081365A1 (fr) * | 2019-10-24 | 2021-04-29 | Prometheus Biosciences, Inc. | Anticorps humanisés contre le ligand 1a de type tnf (tl1a) et leurs utilisations |
MX2022016590A (es) * | 2020-06-26 | 2023-02-01 | Pfizer | Metodos de tratamiento de la enfermedad inflamatoria intestinal con anticuerpos tl1a. |
BR112023009172A2 (pt) * | 2020-11-13 | 2023-10-03 | Cedars Sinai Medical Center | Métodos, sistemas e kits para tratamento de doenças inflamatórias direcionados à tl1a |
CA3207817A1 (fr) * | 2021-02-18 | 2022-08-25 | Allison LUO | Compositions comprenant des anticorps humanises contre le ligand 1a de type tnf (tl1a) et leurs utilisations |
TW202417516A (zh) * | 2022-08-19 | 2024-05-01 | 大陸商四川科倫博泰生物醫藥股份有限公司 | Ptk7結合蛋白及其用途 |
Family Cites Families (128)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4737462A (en) | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
EP0307434B2 (fr) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Anticorps alteres |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
DK0546073T3 (da) | 1990-08-29 | 1998-02-02 | Genpharm Int | Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
GB9325182D0 (en) | 1993-12-08 | 1994-02-09 | T Cell Sciences Inc | Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions |
US6824767B2 (en) | 1994-11-07 | 2004-11-30 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
US7597886B2 (en) | 1994-11-07 | 2009-10-06 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
US20030129189A1 (en) | 1994-11-07 | 2003-07-10 | Guo-Liang Yu | Tumor necrosis factor-gamma |
US7820798B2 (en) | 1994-11-07 | 2010-10-26 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
ATE364614T1 (de) | 1994-11-07 | 2007-07-15 | Human Genome Sciences Inc | Tumornekrose-faktor-gamma |
US6599719B2 (en) | 1994-11-07 | 2003-07-29 | Human Genome Sciences, Inc. | Nucleic acid molecules encoding tumor necrosis factor-gamma-alpha |
US20030198640A1 (en) | 1994-11-07 | 2003-10-23 | Human Genome Sciences, Inc. | Methods and compositions for treating inflammatory bowel diseases relating to human tumor necrosis factor-gamma-beta |
WO2000066608A1 (fr) | 1999-04-30 | 2000-11-09 | Human Genome Sciences, Inc. | Facteur de necrose tumorale gamma |
US6828422B1 (en) | 1995-08-18 | 2004-12-07 | Morphosys Ag | Protein/(poly)peptide libraries |
WO1997008320A1 (fr) | 1995-08-18 | 1997-03-06 | Morphosys Gesellschaft Für Proteinoptimierung Mbh | Banques de proteines/(poly)peptides |
US6632976B1 (en) | 1995-08-29 | 2003-10-14 | Kirin Beer Kabushiki Kaisha | Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene |
US7357927B2 (en) | 1996-03-12 | 2008-04-15 | Human Genome Sciences, Inc. | Death domain containing receptors |
JP4460155B2 (ja) | 1997-12-05 | 2010-05-12 | ザ・スクリプス・リサーチ・インステイチユート | マウス抗体のヒト化 |
US6297367B1 (en) | 1997-12-30 | 2001-10-02 | Chiron Corporation | Polynucleotide encoding TNFL1 |
EP1071458A4 (fr) | 1998-03-13 | 2005-02-16 | Dana Farber Cancer Inst Inc | Anticorps humanises et utilisations correspondantes |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
WO2001002588A2 (fr) | 1999-07-02 | 2001-01-11 | Morphosys Ag | Production de partenaires de liaison specifiques se liant a des (poly)peptides codes par des fragments d'adn genomiques ou est |
US6399857B1 (en) * | 1999-09-22 | 2002-06-04 | Paradigm Genetics, Inc. | Modified nucleotide sequence encoding a LexA DNA binding domain optimized for arabidopsis species |
US20110131679A2 (en) | 2000-04-19 | 2011-06-02 | Thomas La Rosa | Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement |
US6571638B2 (en) | 2000-06-30 | 2003-06-03 | Sawtek, Inc. | Surface-acoustic-wave pressure sensor and associated methods |
AU2001277857A1 (en) | 2000-07-07 | 2002-01-21 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
US6824989B1 (en) | 2000-09-01 | 2004-11-30 | Upstate Biotechnology, Inc. | Recombinant monoclonal antibody to phosphotyrosine-containing proteins |
US20030017518A1 (en) | 2001-06-26 | 2003-01-23 | Joseph Lam | Non-radio-active assay of LPS kinases |
WO2003068821A2 (fr) * | 2002-02-14 | 2003-08-21 | Immunomedics, Inc. | Anticorps anti-cd20 et proteines hybrides desdits anticorps, et methodes d'utilisation |
US7314974B2 (en) * | 2002-02-21 | 2008-01-01 | Monsanto Technology, Llc | Expression of microbial proteins in plants for production of plants with improved properties |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US20090042291A1 (en) | 2002-03-01 | 2009-02-12 | Xencor, Inc. | Optimized Fc variants |
DK2891666T3 (en) | 2002-10-16 | 2017-10-02 | Purdue Pharma Lp | Antibodies that bind cell-associated CA 125 / O722P and methods for its use |
EP1567555A4 (fr) | 2002-11-27 | 2006-06-21 | Biogen Idec Inc | Anticorps humanises diriges contre des proteines chimiotactiques de monocytes |
US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
US20050101889A1 (en) | 2003-11-06 | 2005-05-12 | Freeman Gary A. | Using chest velocity to process physiological signals to remove chest compression artifacts |
EP1781328A4 (fr) * | 2004-07-10 | 2009-06-03 | Alexion Pharma Inc | Techniques de recherche d'anticorps specifiques des cellules cancereuses et anticorps decouverts par ces techniques |
TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
ES2561628T3 (es) | 2005-05-06 | 2016-02-29 | Zymogenetics, Inc. | Anticuerpos monoclonales IL-31 y métodos de uso |
EP1885388B1 (fr) | 2005-05-10 | 2013-09-11 | Biogen Idec MA Inc. | Traitement et evaluation des troubles inflammatoires |
US20090317388A1 (en) | 2005-05-25 | 2009-12-24 | Linda Burkly | Tl1a in treatment of disease |
CN103145838A (zh) * | 2005-06-30 | 2013-06-12 | Abbvie公司 | Il-12/p40结合蛋白 |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
DK1919954T3 (en) | 2005-08-30 | 2017-01-30 | Univ Miami | Immune modulating tumor necrosis factor receptor (TNFR25) - agonists, antagonists and immunotoxins |
CA3149553C (fr) | 2006-06-12 | 2023-11-21 | Aptevo Research And Development Llc | Proteines de liaison monocatenaires polyvalentes dotees d'une fonction d'effecteur |
US7691980B2 (en) | 2007-01-09 | 2010-04-06 | Bio-Rad Laboratories, Inc. | Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers |
US9896511B2 (en) | 2007-01-10 | 2018-02-20 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies |
US20110217310A1 (en) | 2007-01-10 | 2011-09-08 | Siegel Richard M | Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology |
WO2008106579A2 (fr) | 2007-02-28 | 2008-09-04 | Cedars-Sinai Medical Center | Rôle des récepteurs des il-12, il-23 et il-17 dans l'affection intestinale inflammatoire |
KR101248422B1 (ko) * | 2007-11-13 | 2013-04-09 | 테바 바이오파머수티컬스 유에스에이, 아이엔씨. | Tl1a에 대한 인간화된 항체 |
CN101469270B (zh) | 2007-12-27 | 2012-08-22 | 牛斌 | 工业连续化塑料裂解器 |
WO2009092014A1 (fr) | 2008-01-18 | 2009-07-23 | Gagnon Peter S | Purification améliorée d'anticorps et de fragments d'anticorps par chromatographie sur hydroxyapatite |
AU2009296299A1 (en) | 2008-09-29 | 2010-04-01 | Roche Glycart Ag | Antibodies against human IL 17 and uses thereof |
AU2010228990A1 (en) | 2009-03-24 | 2011-10-27 | Teva Biopharmaceuticals Usa, Inc. | Humanized antibodies against LIGHT and uses thereof |
AU2010279637B2 (en) | 2009-08-03 | 2012-08-23 | University Of Miami | Method for in vivo expansion of T regulatory cells |
WO2011106707A2 (fr) | 2010-02-26 | 2011-09-01 | Human Genome Sciences, Inc. | Anticorps qui se lient spécifiquement à dr3 |
ES2553262T3 (es) | 2010-08-25 | 2015-12-07 | F. Hoffmann-La Roche Ag | Anticuerpos contra la IL-18R1 y usos de los mismos |
ES2618586T3 (es) | 2010-09-16 | 2017-06-21 | Baliopharm Ag | Anticuerpo anti-huTNFR1 |
US8766034B2 (en) | 2010-09-22 | 2014-07-01 | Cedars-Sinai Medical Center | TL1A model of inflammation fibrosis and autoimmunity |
JO3375B1 (ar) | 2010-11-08 | 2019-03-13 | Regeneron Pharma | أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a) |
US9902996B2 (en) | 2011-02-11 | 2018-02-27 | Cedars-Sinai Medical Center | Methods of predicting the need for surgery in crohn's disease |
AU2012259312A1 (en) | 2011-05-20 | 2013-12-12 | Government Of The United States, As Represented By The Secretary Department Of Health And Human Services | Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology and antibodies thereof |
WO2012167143A1 (fr) | 2011-06-03 | 2012-12-06 | Xoma Technology Ltd. | Anticorps spécifiques du tgf bêta |
US9890218B2 (en) | 2011-06-30 | 2018-02-13 | Chugai Seiyaku Kabushiki Kaisha | Heterodimerized polypeptide |
WO2013044298A1 (fr) | 2011-09-30 | 2013-04-04 | Cephalon Australia Pty Ltd | Anticorps contre tl1a et leurs utilisations |
WO2013081143A1 (fr) | 2011-11-30 | 2013-06-06 | 中外製薬株式会社 | Support contenant des médicaments dans une cellule pour former un complexe immunitaire |
GB201203051D0 (en) | 2012-02-22 | 2012-04-04 | Ucb Pharma Sa | Biological products |
ES2633894T3 (es) | 2012-08-02 | 2017-09-25 | F. Hoffmann-La Roche Ag | Procedimiento para producir moléculas monoméricas y multiméricas y usos de las mismas |
JP6307077B2 (ja) | 2012-08-02 | 2018-04-04 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 不活性免疫グロブリンFc領域とのFc融合体としての可溶性FcRを生産するための方法およびその使用 |
WO2014051109A1 (fr) * | 2012-09-28 | 2014-04-03 | 協和発酵キリン株式会社 | Anticorps anti-bmp9 humain et agent thérapeutique pour une maladie d'ossification ectopique contenant ledit anticorps comme principe actif |
CN105102618B (zh) | 2012-12-27 | 2018-04-17 | 中外制药株式会社 | 异源二聚化多肽 |
CA2896894A1 (fr) | 2013-01-02 | 2014-07-10 | Glenmark Pharmaceuticals S.A. | Anticorps qui se lient a tl1a et leurs utilisations |
RU2761631C2 (ru) | 2013-03-13 | 2021-12-13 | Дзе Юнайтед Стэйтс Оф Америка, Эс Репрезентед Бай Дзе Секретэри, Департмент Оф Хелт Энд Хьюман Сервисиз | Белки rsv в предшествующей слиянию конформации и их применение |
WO2014144960A2 (fr) | 2013-03-15 | 2014-09-18 | Abbvie Biotherapeutics Inc. | Variants de fc |
EA201890895A1 (ru) | 2013-03-15 | 2019-02-28 | Зинджения, Инк. | Мультивалентные и моновалентные мультиспецифические комплексы и их применение |
NZ714765A (en) * | 2013-06-06 | 2021-12-24 | Pf Medicament | Anti-c10orf54 antibodies and uses thereof |
EP3022295A4 (fr) | 2013-07-19 | 2017-03-01 | Cedars-Sinai Medical Center | Signature de la voie de signalisation de tl1a (tnfsf15) |
PL3044234T3 (pl) | 2013-09-13 | 2020-10-19 | Beigene Switzerland Gmbh | Przeciwciała anty-PD1 i ich zastosowanie jako środków terapeutycznych i diagnostycznych |
EP3068801A1 (fr) | 2013-11-13 | 2016-09-21 | Pfizer Inc. | Anticorps spécifiques du ligand 1a de type facteur de nécrose tumorale et compositions ainsi qu'utilisations associées |
ES2811274T3 (es) * | 2014-04-18 | 2021-03-11 | Univ Leland Stanford Junior | Anticuerpos monoclonales humanizados y quiméricos para CD99 |
TW201622727A (zh) | 2014-05-02 | 2016-07-01 | 泰瓦藥品工業有限公司 | 以延遲釋放型6-巰基嘌呤治療克隆氏症 |
ES2936810T3 (es) | 2014-05-16 | 2023-03-22 | Pfizer | Anticuerpos biespecíficos con interfaces CH1-CL de ingeniería |
US10160805B2 (en) | 2014-07-11 | 2018-12-25 | New York University | Methods of treating inflammatory bowel disease by administering tumor necrosis factor-like ligand 1A or an agonistic death-domain receptor 3 antibody |
CN108064237B (zh) | 2014-11-14 | 2022-02-11 | 豪夫迈·罗氏有限公司 | 包含tnf家族配体三聚体的抗原结合分子 |
MA41460A (fr) | 2015-02-03 | 2017-12-12 | Oncomed Pharm Inc | Agents de liaison à la tnfrsf et leurs utilisations |
EP3973980A1 (fr) | 2015-03-31 | 2022-03-30 | F. Hoffmann-La Roche AG | Molécules de liaison d'antigène comprenant un trimère de ligand de la famille tnf |
WO2016162356A1 (fr) * | 2015-04-07 | 2016-10-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Immunotoxine anti-pd-l1 pour son utilisation en thérapie |
US10647756B2 (en) | 2015-05-18 | 2020-05-12 | Pfizer Inc. | Humanized antibodies |
MA42821A (fr) | 2015-09-15 | 2018-07-25 | Amgen Inc | Protéines de liaison à l'antigène tétraspécifiques et bispécifiques tétravalentes et utilisations de celles-ci |
TWI703158B (zh) | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | 特異性結合tl1a之抗體 |
US10526413B2 (en) | 2015-10-02 | 2020-01-07 | Hoffmann-La Roche Inc. | Bispecific antibodies specific for OX40 |
US20180319889A1 (en) | 2015-11-02 | 2018-11-08 | La Jolla Institute For Allergy & Immunology | Method and medicament for treating airway and/or lung diseases |
ITUB20155097A1 (it) * | 2015-11-05 | 2017-05-05 | Biouniversa Srl | Anticorpi umanizzati anti-BAG3 |
CR20180365A (es) | 2015-12-16 | 2018-09-28 | Amgen Inc | PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS |
KR102527840B1 (ko) | 2016-04-29 | 2023-05-03 | 화이자 인코포레이티드 | 인터페론 베타 항체 및 그의 용도 |
SG11201809793UA (en) * | 2016-05-09 | 2018-12-28 | Bristol Myers Squibb Co | Tl1a antibodies and uses thereof |
CA3031028C (fr) | 2016-07-25 | 2024-02-13 | Lu Wang | Tampon de lavage pour chromatographie par affinite |
CN110121509B (zh) | 2016-10-26 | 2024-05-07 | 西达-赛奈医疗中心 | 中和抗tl1a单克隆抗体 |
WO2018112240A1 (fr) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Traitement d'une maladie du tractus gastro-intestinal avec un inhibiteur du tnf |
JP7036909B2 (ja) | 2017-10-10 | 2022-03-15 | サノフイ | 抗cd38抗体および使用方法 |
TW201930355A (zh) | 2017-12-19 | 2019-08-01 | 英商F星貝塔有限公司 | 結合物件(三) |
CN112585165A (zh) | 2018-04-25 | 2021-03-30 | 普罗米修斯生物科学公司 | 优化的抗tl1a抗体 |
GB201811404D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
CA3106046A1 (fr) | 2018-07-12 | 2020-01-16 | F-Star Beta Limited | Molecules d'anticorps qui se lient a pd-l1 et cd137 |
GB201811408D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
GB201811415D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-Mesothelin Anti bodies |
BR112021000282A2 (pt) | 2018-07-12 | 2021-04-06 | F-Star Beta Limited | Moléculas de anticorpo que se ligam a cd137 e ox40 |
GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
GB201811450D0 (en) | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
EP3864043A1 (fr) | 2018-10-09 | 2021-08-18 | Sanofi | Protéines de liaison anti-cd38, anti-cd28 et anti-cd3 trispécifiques et procédés d'utilisation pour traiter une infection virale |
WO2020086758A1 (fr) | 2018-10-23 | 2020-04-30 | Dragonfly Therapeutics, Inc. | Protéines hétérodimères fusionnées à un fragment fc |
WO2021081365A1 (fr) | 2019-10-24 | 2021-04-29 | Prometheus Biosciences, Inc. | Anticorps humanisés contre le ligand 1a de type tnf (tl1a) et leurs utilisations |
BR112022007720A2 (pt) | 2019-10-24 | 2022-08-23 | Prometheus Biosciences Inc | Anticorpos humanizados para ligante 1a tnf-like (tl1a) e seus usos |
MX2022016590A (es) | 2020-06-26 | 2023-02-01 | Pfizer | Metodos de tratamiento de la enfermedad inflamatoria intestinal con anticuerpos tl1a. |
-
2019
- 2019-04-24 CN CN201980043250.4A patent/CN112585165A/zh active Pending
- 2019-04-24 US US17/050,064 patent/US20210070871A1/en not_active Abandoned
- 2019-04-24 MA MA052366A patent/MA52366A/fr unknown
- 2019-04-24 CA CA3098374A patent/CA3098374A1/fr active Pending
- 2019-04-24 EP EP19792354.3A patent/EP3784699A4/fr active Pending
- 2019-04-24 JP JP2020560230A patent/JP7332627B2/ja active Active
- 2019-04-24 KR KR1020207034024A patent/KR20210005169A/ko not_active Application Discontinuation
- 2019-04-24 AU AU2019261426A patent/AU2019261426A1/en active Pending
- 2019-04-24 WO PCT/US2019/028987 patent/WO2019209995A2/fr unknown
- 2019-04-25 TW TW108114566A patent/TWI842707B/zh active
- 2019-11-25 US US16/694,814 patent/US10689439B2/en active Active
-
2020
- 2020-04-30 US US16/863,971 patent/US11440954B2/en active Active
-
2022
- 2022-09-09 US US17/931,049 patent/US20230192835A1/en active Pending
-
2023
- 2023-08-10 JP JP2023131429A patent/JP2023166402A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2019209995A3 (fr) | 2019-12-12 |
US11440954B2 (en) | 2022-09-13 |
JP2021521843A (ja) | 2021-08-30 |
JP7332627B2 (ja) | 2023-08-23 |
US10689439B2 (en) | 2020-06-23 |
JP2023166402A (ja) | 2023-11-21 |
CN112585165A (zh) | 2021-03-30 |
CA3098374A1 (fr) | 2019-10-31 |
EP3784699A2 (fr) | 2021-03-03 |
WO2019209995A2 (fr) | 2019-10-31 |
EP3784699A4 (fr) | 2022-04-13 |
US20200157203A1 (en) | 2020-05-21 |
US20210070871A1 (en) | 2021-03-11 |
AU2019261426A1 (en) | 2020-12-03 |
TW201945396A (zh) | 2019-12-01 |
KR20210005169A (ko) | 2021-01-13 |
TWI842707B (zh) | 2024-05-21 |
US20200255510A1 (en) | 2020-08-13 |
US20230192835A1 (en) | 2023-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA53434A (fr) | Anticorps anti-tigit | |
MA52884A (fr) | Anticorps anti-il-11 | |
MA47694A (fr) | Anticorps anti-tigit | |
MA49034A (fr) | Anticorps anti-lag3 | |
MA52742A (fr) | Anticorps bispécifiques dll3-cd3 | |
MA47268A (fr) | Anticorps anti-gpc3 | |
DK3625259T3 (da) | Anti-sirpalpha-antistoffer | |
MA46057A (fr) | Anticorps anti-ctla4 | |
MA50505A (fr) | Anticorps 2 + 1 bispécifiques (contorsbodies) | |
MA52212A (fr) | Anticorps multivalent | |
MA52366A (fr) | Anticorps anti-tl1a optimisés | |
MA46041A (fr) | Anticorps anti-tim -3 | |
MA45004A (fr) | Anticorps spécifiques anti-wt1-hla | |
MA50352A (fr) | Anticorps multispécifiques | |
MA52152A (fr) | Anticorps | |
MA53905A (fr) | Anticorps stabilisant trem2 | |
MA49749A (fr) | Anticorps anti-cd137 | |
DK3544636T3 (da) | Pyrrolobenzodiazepin-antistof-konjugater | |
MA45231A (fr) | Anticorps anti-ige | |
DK3606961T3 (da) | Garp-tgf-beta-antistoffer | |
DK3504241T3 (da) | Anti-cd3-antistofformuleringer | |
MA44236A (fr) | Anticorps anti-tgfbêta 2 | |
MA51134A (fr) | Anticorps anti-alpha-synucléine | |
MA42843A (fr) | Anticorps anti-cd115 | |
MA49250A (fr) | Nouveaux anticorps anti-cd3 |